Products for Research Use Only
RegisterLogin

RapaLink-1

CAT: 0804-HY-111373-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-111373-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity[1][2].
CAS Number
1887095-82-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; mTOR
Type
Reference compound
Related Pathways
Autophagy; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rapalink-1.html
Purity
99.65
Solubility
DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL
Smiles
NC1=C(C2=NC=N1)C(C3=CC=C(O4)C(N=C4N)=C3)=NN2CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N5)C=C5COCCO[C@H](CC[C@H]6C[C@H]([C@@](CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H]7C)C)=O)OC)O)\C)C)=O)([H])OC([C@@](CCCC8)([H])N8C(C([C@@]9(O[C@@](C[C@@H](/C(C)=C/C=C/C=C/7)OC)([H])CC[C@H]9C)O)=O)=O)=O)C)[C@@H](C6)OC)=O
Molecular Formula
C91H138N12O24
Molecular Weight
1784.14
Precautions
H302, H315, H319, H335
References & Citations
[1]Fan Q, et al. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Cancer Cell. 2017 Mar 13;31 (3) :424-435.|[2]Kuroshima K, et al. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against SU 11248-resistant renal cell carcinoma. Cancer Sci. 2020 May;111 (5) :1607-1618.|[3]Mu F, et al. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy both in vivo and vitro. Biochem Biophys Res Commun. 2020 Apr 30;525 (2) :384-391.|[4]Rodrik-Outmezguine VS, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016 Jun 9;534 (7606) :272-6.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MTOR

Related Products

CatalogName
HY-N6838-011,1,1,1-Kestohexaose
HY-157129AMPK-α1β1γ1 activator 1
HY-1336231,1,1-Tribromoacetone
HY-149536TWIK-1/TREK-1-IN-1
HY-W160628S1,1,1-Trimethoxypropane-d5
HY-133630-011-Bromo-1,1-dichloroacetone
HY-W881439-011- (1,1-Dimethylethyl) tridecanedioate
HY-W032015S11-Bromooctane-1,1-d2
HY-1336291,1,1,3-Tetrachloroacetone
HY-112773-011,1′,1′′,1′′′-[1,4-Piperazinediylbis (2,1-ethanediylnitrilo) ]tetrakis[2-dodecanol]

Alternative Products

CatalogName
MAD09582-01Rapalink-1
OF59775-011,1,1,1,1-Kestoheptaose
N2864-5.11,1,1,1-Kestohexaose
1120401,1,1,1-Kestohexose

Popular Products